Funding Opportunity PA-24-184 from the NIH Guide for Grants and Contracts. The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research.

Notice NOT-AI-24-037 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-25-039 from the NIH Guide for Grants and Contracts. This concept proposes to advance methodological rigor in NIDA-relevant research by supporting training on the responsible analyses of complex, large-scale datasets involving brain, behavioral, genomic, and socioenvironmental data through: 1. Courses for Skills Development 2. Curriculum or Methods Development

Notice NOT-NS-24-071 from the NIH Guide for Grants and Contracts

Notice NOT-MH-24-190 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-24-013 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support multi-project research programs for the development, characterization, and advancement of gene- and cell-based approaches to achieve long-term remission or elimination of HIV. Approaches will eventually be evaluated in the clinic, rendered scalable and deliverable. Applications are expected to include basic science discovery as well as preclinical research activities such as test-of-concept studies in animal models. Applicants are required to include one or more private sector partner to participate in their program.

Notice NOT-OD-24-087 from the NIH Guide for Grants and Contracts

Notice NOT-DA-24-024 from the NIH Guide for Grants and Contracts

Notice NOT-HS-24-011 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-TR-24-021 from the NIH Guide for Grants and Contracts. This is a non-competitive funding opportunity intended to fund a single award. NCATS is announcing its intent to issue a single source cooperative agreement to Cincinnati Childrens Hospital Medical Center (CCHMC) to support the Data Management and Coordinating Center. The Rare Diseases Clinical Research Network (RDCRN) is intended to advance and improve diagnosis, management, and treatment of numerous, diverse rare diseases through highly collaborative, multi-site, patient-centric, translational, and clinical research with an emphasis on early and timely identification of individuals with rare diseases and clinical trial readiness. The DMCC facilitates and supports the activities of each individual Rare Diseases Clinical Research Consortium (RDCRC) along with trans-network activities that broadly facilitate the advancement of rare disease research via four avenues: administrative support, data management support, clinical research support and patient engagement, and broad dissemination of information. The RDCRCs will continue conducting research conducted under a separate NOFO.

Notice NOT-GM-24-032 from the NIH Guide for Grants and Contracts

Notice NOT-HG-24-029 from the NIH Guide for Grants and Contracts

Notice NOT-HG-24-030 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-196 from the NIH Guide for Grants and Contracts. (Reissue of RFA-NS-16-021, PAR-18-413, RFA-NS-19-039) Diffuse brain white matter disease is highly prevalent in the elderly, and has been clinically associated with vascular contributions to cognitive impairment and dementia (VCID) in both men and women. Diffuse white matter disease is thought to include a variety of pathologies including demyelination and/or fiber loss due to multifocal infarction and local ischemia. It is often accompanied by arteriosclerosis in deep penetrating arteries, multiple infarcts in the basal ganglia, brainstem or cerebellum. Though most commonly extending out from the periventricular surfaces, it may also occur in subcortical white matter. Diffuse white matter disease is typically detected in clinical settings as hyperintensity on magnetic resonance imaging (MRI) or signal loss on computed tomography x-ray (CT) scan; diffuse white matter disease can be detected histologically as well, for example in human pathology and in studies using animal models. Despite the prevalence and potential significance of white matter disease for cerebrovascular disease etiology and cognitive outcomes, much remains to be learned about the cellular and molecular causes, regional vulnerability, and progression over time. The physiological consequences of diffuse white matter disease on local axon and neural circuit function are almost completely unknown. The purpose of this FOA is to address some of the many gaps in knowledge of the biologic mechanisms of the commonly occurring, cerebrovascular disease and age-related diffuse white matter disease at the molecular, cellular, tissue and brain circuit level. The ultimate goal of this fundamental research is to inform future efforts to reduce the burden of illness due to age-related vascular contributions to cognitive impairment and dementia.

Notice NOT-OD-24-088 from the NIH Guide for Grants and Contracts

Notice NOT-CA-24-042 from the NIH Guide for Grants and Contracts

Notice NOT-MH-24-210 from the NIH Guide for Grants and Contracts

Notice NOT-DA-24-021 from the NIH Guide for Grants and Contracts

Notice NOT-DA-24-023 from the NIH Guide for Grants and Contracts

Notice NOT-DA-24-013 from the NIH Guide for Grants and Contracts